Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.55 |
| ▸ | PTGER1 | P34995 | 14/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.45 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL27709152 | 0.98 | CYP1A2 (0.52) | CYP1A2PTGER1MRGPRX4CYP2C9MAPT | |
| SCHEMBL3212344 | 0.86 | PTGER1 (0.55) | CYP1A2PTGER1MRGPRX4CYP2C9TBXA2R | |
| SCHEMBL14397613 | 0.86 | CYP1A2 (0.52) | CYP1A2PTGER1MRGPRX4CYP2C9MAPT | |
| SCHEMBL13902814 | 0.85 | PTGER1 (0.50) | CYP1A2PTGER1CYP2C9MAPTTBXA2R | |
| SCHEMBL3214226 | 0.84 | CYP1A2 (0.50) | CYP1A2PTGER1MRGPRX4CYP2C9MAPT | |
| SCHEMBL2962415 | 0.83 | PTGER1 (0.58) | CYP1A2PTGER1MRGPRX4CYP2C9TBXA2R | |
| SCHEMBL13902801 | 0.82 | PTGER1 (0.54) | CYP1A2PTGER1MRGPRX4CYP2C9MAPT | |
| SCHEMBL2956473 | 0.82 | PTGER1 (0.62) | CYP1A2PTGER1MRGPRX4CYP2C9MAPT | |
| SCHEMBL13902798 | 0.81 | PTGER1 (0.50) | CYP1A2PTGER1CYP2C9TBXA2RPTGS1 | |
| SCHEMBL2954555 | 0.81 | PTGER1 (0.77) | CYP1A2PTGER1CYP2C9TBXA2RPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759369-B2 | Pyridine compounds for the treatment of prostaglandin mediated diseases | GLAXO GROUP LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-7759369-B2 | Pyridine compounds for the treatment of prostaglandin mediated diseases | GLAXO GROUP LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-7759369-B2 | Pyridine compounds for the treatment of prostaglandin mediated diseases | GLAXO GROUP LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-20100137378-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20100137378-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20100137378-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20100056527-A1 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED | 2010-03-04 | — | — | US | disclosed |
| US-20100056527-A1 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED | 2010-03-04 | — | — | US | disclosed |
| US-20100056527-A1 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED | 2010-03-04 | — | — | US | disclosed |
| EP-2129670-A2 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | Glaxo Group Limited (GB) | 2009-12-09 | — | — | EP | disclosed |
| US-20080249138-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | MARTIN PAUL GIBLIN GERARD | 2008-10-09 | — | — | US | disclosed |
| US-20080249138-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | MARTIN PAUL GIBLIN GERARD | 2008-10-09 | — | — | US | disclosed |
| US-20080249138-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | MARTIN PAUL GIBLIN GERARD | 2008-10-09 | — | — | US | disclosed |
| WO-2008098978-A2 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008098978-A2 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
| CN-101128430-A | Pyridine compounds for the treatment of prostaglandin mediated diseases | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | CN | disclosed |
| WO-2007113289-A1 | BENZOFURAN COMPOUNDS AS EP1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113289-A1 | BENZOFURAN COMPOUNDS AS EP1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| EP-1833795-A1 | PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006066968-A1 | PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137378-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | PTGER1, PTGDR, PTGER2 | CYP1A2 241/4885PTGER1 1/4885MRGPRX4 25/4885 |
| US-20080249138-A1 | Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases | PTGER1, PTGDR, PTGER4 | CYP1A2 140/4885PTGER1 1/4885MRGPRX4 32/4885 |
| US-20100056527-A1 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | PTGER1, PTGER2, PTGER4 | CYP1A2 69/4885PTGER1 1/4885MRGPRX4 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.